Back to Search
Start Over
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients
- Publication Year :
- 2019
-
Abstract
- Immune-related adverse events (irAEs) developed during immunotherapy with anti-PD-1 agents, could be a predictive surrogate marker of clinical benefit in patients with advanced non-small-cell lung cancer (NSCLC).Patients with NSCLC, treated with anti-PD-1 agents, were retrospectively evaluated. Univariate and multivariate analyses were performed to evaluate the relationships between types of irAEs (differentiated according to system/organ involved and to single-site/multiple-site), overall response rate (ORR), progression-free survival (PFS) and overall survival (OS). We further performed a 6-week landmark analysis.A total of 559 patients were enrolled; 231 patients (41.3%) developed irAEs of any grade and 50 patients (8.9%) G3/G4 events; 191 of them (82.6%) developed "single-site" irAEs and 40 (17.4%) "multiple-site" irAEs. At multivariate analysis, higher ORR was related to irAEs of any grade (P .0001), "single-site" irAEs (P .0001), endocrine (P = .0043) and skin irAEs (P = .0005). Longer PFS was related to irAEs of any grade (P .0001), "single-site" irAEs (P .0001), "multiple-site" irAEs (P = .0374), endocrine irAEs (P = .0084) and skin irAEs (P = .0001). Longer OS was related to irAEs of any grade (P .0001), "single-site" irAEs (P .0001), endocrine irAEs (P = .0044), gastrointestinal irAEs (P = .0437), skin irAEs (P = .0006), and others irAEs (P = .0378). At the 6-week landmark analysis, irAEs of any grade was confirmed an independent predictor of higher ORR, longer PFS, and longer OS.Our study confirmed that irAEs are concordantly related to higher ORR, longer PFS, and longer OS with anti-PD-1 immunotherapy in patients with NSCLC.
- Subjects :
- 0301 basic medicine
Oncology
Cancer Research
Multivariate analysis
medicine.medical_treatment
Pembrolizumab
carcinoma
NSCLC
survival analysis
0302 clinical medicine
Immune-related adverse events
Carcinoma, Non-Small-Cell Lung
italy
middle aged
80 and over
antibodies
humans
Aged, 80 and over
humanized
adult
aged
retrospective studies
female
Nivolumab
030220 oncology & carcinogenesis
young adult
Immunotherapy
Pulmonary and Respiratory Medicine
medicine.medical_specialty
immune system diseases
monoclonal
lung neoplasms
Antibodies, Monoclonal, Humanized
programmed cell death 1 receptor
03 medical and health sciences
Immune system
male
Internal medicine
medicine
Adverse effect
Lung cancer
business.industry
Surrogate endpoint
medicine.disease
non-small-cell lung
030104 developmental biology
drug-related side effects and adverse reactions
treatment outcome
immune-related adverse events
immunotherapy
nivolumab
nsclc
pembrolizumab
business
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....cca8939b2945a2c7d3de69bcb152d4d0